» Articles » PMID: 22796468

Orexin A Decreases Lipid Peroxidation and Apoptosis in a Novel Hypothalamic Cell Model

Overview
Journal Neurosci Lett
Specialty Neurology
Date 2012 Jul 17
PMID 22796468
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Current data support the idea that hypothalamic neuropeptide orexin A (OxA; hypocretin 1) mediates resistance to high fat diet-induced obesity. We previously demonstrated that OxA elevates spontaneous physical activity (SPA), that rodents with high SPA have higher endogenous orexin sensitivity, and that OxA-induced SPA contributes to obesity resistance in rodents. Recent reports show that OxA can confer neuroprotection against ischemic damage, and may decrease lipid peroxidation. This is noteworthy as independent lines of evidence indicate that diets high in saturated fats can decrease SPA, increase hypothalamic apoptosis, and lead to obesity. Together data suggest OxA may protect against obesity both by inducing SPA and by modulation of anti-apoptotic mechanisms. While OxA effects on SPA are well characterized, little is known about the short- and long-term effects of hypothalamic OxA signaling on intracellular neuronal metabolic status, or the physiological relevance of such signaling to SPA. To address this issue, we evaluated the neuroprotective effects of OxA in a novel immortalized primary embryonic rat hypothalamic cell line. We demonstrate for the first time that OxA increases cell viability during hydrogen peroxide challenge, decreases hydrogen peroxide-induced lipid peroxidative stress, and decreases caspase 3/7 induced apoptosis in an in vitro hypothalamic model. Our data support the hypothesis that OxA may promote obesity resistance both by increasing SPA, and by influencing survival of OxA-responsive hypothalamic neurons. Further identification of the individual mediators of the anti-apoptotic and peroxidative effects of OxA on target neurons could lead to therapies designed to maintain elevated SPA and increase obesity resistance.

Citing Articles

Hypocretin (Orexin) Replacement Therapies.

Seigneur E, De Lecea L Med Drug Discov. 2024; 8.

PMID: 38738170 PMC: 11086741. DOI: 10.1016/j.medidd.2020.100070.


Effects of bright light therapy on neuroinflammatory and neuroplasticity markers in a diurnal rodent model of Seasonal Affective Disorder.

Costello A, Linning-Duffy K, Vandenbrook C, Lonstein J, Yan L Ann Med. 2023; 55(2):2249015.

PMID: 37625385 PMC: 10461522. DOI: 10.1080/07853890.2023.2249015.


RNAseq Analysis of FABP4 Knockout Mouse Hippocampal Transcriptome Suggests a Role for WNT/β-Catenin in Preventing Obesity-Induced Cognitive Impairment.

So S, Nixon J, Bernlohr D, Butterick T Int J Mol Sci. 2023; 24(4).

PMID: 36834799 PMC: 9961923. DOI: 10.3390/ijms24043381.


A molecular network map of orexin-orexin receptor signaling system.

Chatterjee O, Gopalakrishnan L, Pullimamidi D, Raj C, Yelamanchi S, Gangadharappa B J Cell Commun Signal. 2022; 17(1):217-227.

PMID: 36480100 PMC: 10030760. DOI: 10.1007/s12079-022-00700-3.


Microglial FABP4-UCP2 Axis Modulates Neuroinflammation and Cognitive Decline in Obese Mice.

So S, Fleming K, Duffy C, Nixon J, Bernlohr D, Butterick T Int J Mol Sci. 2022; 23(8).

PMID: 35457171 PMC: 9032181. DOI: 10.3390/ijms23084354.


References
1.
Karteris E, Machado R, Chen J, Zervou S, Hillhouse E, Randeva H . Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. Am J Physiol Endocrinol Metab. 2005; 288(6):E1089-100. DOI: 10.1152/ajpendo.00351.2004. View

2.
Sikder D, Kodadek T . The neurohormone orexin stimulates hypoxia-inducible factor-1 activity. Genes Dev. 2007; 21(22):2995-3005. PMC: 2049199. DOI: 10.1101/gad.1584307. View

3.
Dohi K, Ripley B, Fujiki N, Ohtaki H, Shioda S, Aruga T . CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH). Peptides. 2005; 26(11):2339-43. DOI: 10.1016/j.peptides.2005.04.004. View

4.
Sang N, Stiehl D, Bohensky J, Leshchinsky I, Srinivas V, Caro J . MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem. 2003; 278(16):14013-9. PMC: 4518846. DOI: 10.1074/jbc.M209702200. View

5.
Harada S, Fujita-Hamabe W, Tokuyama S . Effect of orexin-A on post-ischemic glucose intolerance and neuronal damage. J Pharmacol Sci. 2011; 115(2):155-63. DOI: 10.1254/jphs.10264fp. View